Preliminary Communication

Mitochondrial D-loop methylation levels inversely correlate with disease duration in amyotrophic lateral sclerosis

*Author for correspondence:

E-mail Address: andrea.stoccoro@unipi.it

Department of Translational Research & of New Surgical & Medical Technologies, Laboratory of Medical Genetics, University of Pisa, Medical School, Via Roma 55, Pisa, 56126, Italy

Search for more papers by this author

Adam R Smith

https://orcid.org/0000-0001-6495-2711

Department of Clinical & Biomedical Sciences, Faculty of Health & Life Sciences, University of Exeter, Exeter, EX2 5DW, UK

Search for more papers by this author

Lorena Mosca

Medical Genetics Unit, Department of Medical Services, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy

Search for more papers by this author

Alessandro Marocchi

Medical Genetics Unit, Department of Medical Services, ASST Grande Ospedale Metropolitano Niguarda, Milan, 20162, Italy

Search for more papers by this author

Francesca Gerardi

NEMO Clinical Center, Fondazione Serena Onlus, Milan, 20162, Italy

Search for more papers by this author

Christian Lunetta

Istituti Clinici Scientifici Maugeri IRCCS, Neurorehabilitation Unit of Milan Institute, Milan, 20138, Italy

Search for more papers by this author

Katie Lunnon

https://orcid.org/0000-0001-7570-6065

Department of Clinical & Biomedical Sciences, Faculty of Health & Life Sciences, University of Exeter, Exeter, EX2 5DW, UK

Search for more papers by this author

Lucia Migliore

Department of Translational Research & of New Surgical & Medical Technologies, Laboratory of Medical Genetics, University of Pisa, Medical School, Via Roma 55, Pisa, 56126, Italy

Search for more papers by this author

Fabio Coppedè

**Author for correspondence:

E-mail Address: fabio.coppede@unipi.it

https://orcid.org/0000-0002-3081-6647

Department of Translational Research & of New Surgical & Medical Technologies, Laboratory of Medical Genetics, University of Pisa, Medical School, Via Roma 55, Pisa, 56126, Italy

Interdepartmental Research Center of Biology & Pathology of Aging, University of Pisa, Pisa, 56126, Italy

Search for more papers by this author

Published Online:5 Feb 2024https://doi.org/10.2217/epi-2023-0265

View article

Abstract

Aim: To correlate mitochondrial D-loop region methylation levels and mtDNA copy number with disease duration in familial amyotrophic lateral sclerosis (ALS) patients. Patients & methods: The study population included 12 ALS patients with a mutation in SOD1 and 13 ALS patients with the C9orf72 hexanucleotide repeat expansion. Methylation levels of the D-loop region and mtDNA copy number were quantified using pyrosequencing and quantitative PCR, respectively. Results: We observed that D-loop methylation levels inversely correlated while mtDNA copy number positively correlated with disease duration. Conclusion: Considering the central role played by mitochondria in ALS, this preliminary study provides new knowledge for future studies aimed at identifying biomarkers of disease progression and new targets for therapeutic interventions.

Plain language summary

Amyotrophic lateral sclerosis is a devastating neurodegenerative disease which leads to the patient’s death a few years after the onset of the first symptoms. There are currently no treatments to cure the disease, and the only drugs available are able to prolong patients’ lives by only a few months. Patients may have much variability in the presentation of symptoms, including different duration of disease. This study aims to research whether mitochondrial DNA methylation, a mechanism involved in the biology of the mitochondrion, is associated with the duration of the disease. We observed that methylation of mitochondrial DNA inversely correlates with the disease duration, providing new knowledge for future studies aimed at identifying biomarkers of disease progression.

Tweetable abstract

Peripheral blood mitochondrial DNA methylation inversely correlates with disease duration in amyotrophic lateral sclerosis patients.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur. J. Neurol. 27(10), 1918–1929 (2020).
Medline CASGoogle Scholar
2. Smith EF, Shaw PJ, De Vos KJ. The role of mitochondria in amyotrophic lateral sclerosis. Neurosci. Lett. 710, 132933 (2019). • Interesting review of the role of mitochondrial dysfunction in the etiology of amyotrophic lateral sclerosis (ALS).
MedlineGoogle Scholar
3. Wong W. Managed care considerations to improve health care utilization for patients with ALS. Am. J. Manag. Care 29, S120–S126 (2023).
MedlineGoogle Scholar
4. Smukowski SN, Maioli H, Latimer CS, Bird TD, Jayadev S, Valdmanis PN. Progress in amyotrophic lateral sclerosis gene discovery: reflecting on classic approaches and leveraging emerging technologies. Neurol. Genet. 8(3), e669 (2022).
MedlineGoogle Scholar
5. Wang H, Guan L, Deng M. Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy. Front. Neurosci. 17, 1170996 (2023).
MedlineGoogle Scholar
6. Mead RJ, Shan N, Reiser HJ, Marshall F, Shaw PJ. Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat. Rev. Drug Discov. 22(3), 185–212 (2023).
Medline CASGoogle Scholar
7. Chen W, Guo L, Li M, Wei C, Li S, Xu R. The pathogenesis of amyotrophic lateral sclerosis: mitochondrial dysfunction, protein misfolding and epigenetics. Brain Res. 1786, 147904 (2022).
Medline CASGoogle Scholar
8. Berson A, Nativio R, Berger SL, Bonini NM. Epigenetic regulation in neurodegenerative diseases. Trends Neurosci. 41(9), 587–598 (2018).
Medline CASGoogle Scholar
9. Dolinar A, Ravnik-Glavač M, Glavač D. Epigenetic mechanisms in amyotrophic lateral sclerosis: a short review. Mech. Ageing Dev. 174, 103–110 (2018). • Comprehensive review on the role of epigenetic mechanisms in ALS pathogenesis.
Medline CASGoogle Scholar
10. Cai Z, Jia X, Liu M, Yang X, Cui L. Epigenome-wide DNA methylation study of whole blood in patients with sporadic amyotrophic lateral sclerosis. Chin. Med. J. (Engl.) 135(12), 1466–1473 (2022).
Medline CASGoogle Scholar
11. Zhang M, Tartaglia MC, Moreno D et al. DNA methylation age-acceleration is associated with disease duration and age at onset in C9orf72 patients. Acta Neuropathol. 134(2), 271–279 (2017).
Medline CASGoogle Scholar
12. Xi Z, Zinman L, Moreno D et al. Hypermethylation of the CpG island near the G4C2 repeat in ALS with a C9orf72 expansion. Am. J. Hum. Genet. 92(6), 981–989 (2013).
Medline CASGoogle Scholar
13. Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ. Epigenetic regulation of motor neuron cell death through DNA methylation. J. Neurosci. 31(46), 16619–16636 (2011). • Reports the first evidence of the role of mtDNA methylation in motor neurons.
Medline CASGoogle Scholar
14. Wong M, Gertz B, Chestnut BA, Martin LJ. Mitochondrial DNMT3A and DNA methylation in skeletal muscle and CNS of transgenic mouse models of ALS. Front. Cell. Neurosci. 7, 279 (2013). •• Interesting paper that reports that mtDNA methylation patterns are abnormal in the skeletal muscle and spinal cord of presymptomatic ALS mice.
Medline CASGoogle Scholar
15. Stoccoro A, Mosca L, Carnicelli V et al. Mitochondrial DNA copy number and D-loop region methylation in carriers of amyotrophic lateral sclerosis gene mutations. Epigenomics 10(11), 1431–1443 (2018). • First evidence of mtDNA methylation alteration in peripheral blood of ALS patients.
CASGoogle Scholar
16. Stoccoro A, Smith AR, Mosca L et al. Reduced mitochondrial D-loop methylation levels in sporadic amyotrophic lateral sclerosis. Clin. Epigenetics 2(1), 137 (2020).
Google Scholar
17. Stoccoro A, Smith AR, Baldacci F et al. Mitochondrial D-loop region methylation and copy number in peripheral blood DNA of Parkinson’s disease patients. Genes (Basel) 12(5), 720 (2021).
Medline CASGoogle Scholar
18. Byun HM, Barrow TM. Analysis of pollutant-induced changes in mitochondrial DNA methylation. Methods Mol. Biol. 1265, 271–283 (2015).
Medline CASGoogle Scholar
19. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron. Disord. 1(5), 293–299 (2000).
Medline CASGoogle Scholar
20. Millecamps S, Salachas F, Cazeneuve C et al. SOD1, ANG, VAPB, TARDBP, and FUS mutations in familial amyotrophic lateral sclerosis: genotype-phenotype correlations. J. Med. Genet. 47(8), 554–560 (2010).
Medline CASGoogle Scholar
21. Renton AE, Majounie E, Waite A et al. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 72(2), 257–268 (2011).
Medline CASGoogle Scholar
22. Tarlarini C, Lunetta C, Mosca L et al. Novel FUS mutations identified through molecular screening in a large cohort of familial and sporadic amyotrophic lateral sclerosis. Eur. J. Neurol. 22(11), 1474–1481 (2015).
Medline CASGoogle Scholar
23. Crugnola V, Lamperti C, Lucchini V et al. Mitochondrial respiratory chain dysfunction in muscle from patients with amyotrophic lateral sclerosis. Arch. Neurol. 67(7), 849–854 (2010).
MedlineGoogle Scholar
24. Hirano M, Angelini C, Montagna P et al. Amyotrophic lateral sclerosis with ragged-red fibers. Arch. Neurol. 65(3), 403–406 (2008).
MedlineGoogle Scholar
25. Zhao J, Wang X, Huo Z et al. The impact of mitochondrial dysfunction in amyotrophic lateral sclerosis. Cells 11(13), 2049 (2022).
Medline CASGoogle Scholar
26. Candelise N, Salvatori I, Scaricamazza S et al. Mechanistic insights of mitochondrial dysfunction in amyotrophic lateral sclerosis: an update on a lasting relationship. Metabolites 12(3), 233 (2022).
Medline CASGoogle Scholar
27. Shrivastava M, Vivekanandhan S, Pati U, Behari M, Das TK. Mitochondrial perturbance and execution of apoptosis in platelet mitochondria of patients with amyotrophic lateral sclerosis. Int. J. Neurosci. 121(3), 149–158 (2011).
MedlineGoogle Scholar
28. Ladd AC, Keeney PM, Govind MM, Bennett JP Jr. Mitochondrial oxidative phosphorylation transcriptome alterations in human amyotrophic lateral sclerosis spinal cord and blood. Neuromolecular Med. 16(4), 714–726 (2014).
Medline CASGoogle Scholar
29. Ehinger JK, Morota S, Hansson MJ, Paul G, Elmér E. Mitochondrial dysfunction in blood cells from amyotrophic lateral sclerosis patients. J. Neurol. 262(6), 1493–1503 (2015).
Medline CASGoogle Scholar
30. Calió ML, Henriques E, Siena A, Bertoncini CRA, Gil-Mohapel J, Rosenstock TR. Mitochondrial dysfunction, neurogenesis, and epigenetics: putative implications for amyotrophic lateral sclerosis neurodegeneration and treatment. Front. Neurosci. 14, 679 (2020).
MedlineGoogle Scholar
31. Lopes AFC. Mitochondrial metabolism and DNA methylation: a review of the interaction between two genomes. Clin. Epigenetics 12(1), 182 (2020).
MedlineGoogle Scholar
32. Stoccoro A, Coppedè F. Mitochondrial DNA methylation and human diseases. Int. J. Mol. Sci. 22(9), 4594 (2021). • Comprehensive review on the role of mitochondrial epigenetic mechanisms in human diseases.
Medline CASGoogle Scholar
33. Fernández-Silva P, Enriquez JA, Montoya J. Replication and transcription of mammalian mitochondrial DNA. Exp. Physiol. 88(1), 41–56 (2003).
Medline CASGoogle Scholar
34. Coppedè F, Stoccoro A, Mosca L et al. Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations. Amyotroph. Lateral Scler. Frontotemporal Degener. 19(1–2), 93–101 (2018).
Medline CASGoogle Scholar
35. Hop PJ, Zwamborn RAJ, Hannon E et al. Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS. Sci. Transl. Med. 14(633), eabj0264 (2022).
Medline CASGoogle Scholar
36. Ruf WP, Hannon E, Freischmidt A et al. Methylome analysis of ALS patients and presymptomatic mutation carriers in blood cells. Neurobiol. Aging 116, 16–24 (2022).
Medline CASGoogle Scholar
37. Zhang M, Xi Z, Ghani M et al. Genetic and epigenetic study of ALS-discordant identical twins with double mutations in SOD1 and ARHGEF28. J. Neurol. Neurosurg. Psychiatry 87(11), 1268–1270 (2016).
MedlineGoogle Scholar
38. Zhang M, McKeever PM, Xi Z et al. DNA methylation age acceleration is associated with ALS age of onset and survival. Acta Neuropathol. 139(5), 943–946 (2020).
MedlineGoogle Scholar
39. Gao J, Wen S, Zhou H, Feng S. De-methylation of displacement loop of mitochondrial DNA is associated with increased mitochondrial copy number and nicotinamide adenine dinucleotide subunit 2 expression in colorectal cancer. Mol. Med. Rep. 12(5), 7033–7038 (2015).
Medline CASGoogle Scholar
40. Tong H, Zhang L, Gao J, Wen S, Zhou H, Feng S. Methylation of mitochondrial DNA displacement loop region regulates mitochondrial copy number in colorectal cancer. Mol. Med. Rep. 16(4), 5347–5353 (2017).
Medline CASGoogle Scholar
41. Sanyal T, Bhattacharjee P, Bhattacharjee S, Bhattacharjee P. Hypomethylation of mitochondrial D-loop and ND6 with increased mitochondrial DNA copy number in the arsenic-exposed population. Toxicology 408, 54–61 (2018).
Medline CASGoogle Scholar
42. Fernández-Silva P, Enriquez JA, Montoya J. Replication and transcription of mammalian mitochondrial DNA. Exp. Physiol. 88(1), 41–56 (2003).
Medline CASGoogle Scholar
43. Shock LS, Thakkar PV, Peterson EJ, Moran RG, Taylor SM. DNA methyltransferase 1, cytosine methylation, and cytosine hydroxymethylation in mammalian mitochondria. Proc. Natl Acad. Sci. USA 108(9), 3630–3635 (2011).
Medline CASGoogle Scholar
44. Patil V, Cuenin C, Chung F et al. Human mitochondrial DNA is extensively methylated in a non-CpG context. Nucleic Acids Res. 47(19), 10072–10085 (2019).
Medline CASGoogle Scholar
45. Dostal V, Churchill MEA. Cytosine methylation of mitochondrial DNA at CpG sequences impacts transcription factor A DNA binding and transcription. Biochim. Biophys Acta Gene Regul. Mech. 1862(5), 598–607 (2019).
Medline CASGoogle Scholar
46. Harvey C, Weinreich M, Zhang S et al. Mitochondrial function determines severity but not risk of amyotrophic lateral sclerosis. bioRxiv www.biorxiv.org/content/10.1101/2022.05.31.494229v1
Google Scholar
47. Zhou J, Li A, Li X, Yi J. Dysregulated mitochondrial Ca²⁺ and ROS signaling in skeletal muscle of ALS mouse model. Arch. Biochem. Biophys. 663, 249–258 (2019).
Medline CASGoogle Scholar
48. Joshi AU, Saw NL, Vogel H, Cunnigham AD, Shamloo M, Mochly-Rosen D. Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis. EMBO Mol. Med. 10(3), e8166 (2018).
MedlineGoogle Scholar
49. Joardar A, Manzo E, Zarnescu DC. Metabolic dysregulation in amyotrophic lateral sclerosis: challenges and opportunities. Curr. Genet. Med. Rep. 5(2), 108–114 (2017).
MedlineGoogle Scholar
50. Sahafnejad Z, Ramazi S, Allahverdi A. An update of epigenetic drugs for the treatment of cancers and brain diseases: a comprehensive review. Genes (Basel) 14(4), 873 (2023).
Medline CASGoogle Scholar
51. Coppede F. Targeting the epigenome to treat neurodegenerative diseases or delay their onset: a perspective. Neural Regen. Res. 17(8), 1745–1747 (2022).
Medline CASGoogle Scholar
52. Nguyen S, Meletis K, Fu D, Jhaveri S, Jaenisch R. Ablation of de novo DNA methyltransferase Dnmt3a in the nervous system leads to neuromuscular defects and shortened lifespan. Dev. Dyn. 236(6), 1663–1676 (2007).
Medline CASGoogle Scholar
53. Mehta AR, Walters R, Waldron FM et al. Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis. Brain Commun. 1(1), fcz009 (2019).
MedlineGoogle Scholar

Vol. 16, No. 4

Supplemental Materials

Metrics

Downloaded 80 times

History

Received 21 July 2023

Accepted 17 January 2024

Published online 5 February 2024

Published in print February 2024

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/epi-2023-0265

Author contributions

F Coppedè, A Stoccoro and L Migliore designed the study. L Mosca, C Lunetta, A Marocchi and F Gerardi collected the samples and provided the clinical data of the patients. A Stoccoro and A Smith performed the experiments. A Stoccoro, A Smith and K Lunnon generated the experimental data. A Stoccoro and F Coppedè wrote the manuscript. All authors edited the paper and approved the final manuscript.

Acknowledgments

The authors thank Associazione ‘Io corro con Giovanni’ www.iocorrocongiovanni.org; info@iocorrocongiovanni.org; Paina di Giussano-Via IV Novembre 20-c/o Centro Associativo ‘Generazioni’, for their initial support for starting our research in SOD1 and C9orf72 families.

Financial disclosure

The present study was supported by the researcher’s intramural funds (ATENEO Funds, University of Pisa). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Competing interests disclosure

The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

Writing disclosure

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The Ethics Committee of Pisa University approved the study (protocol no. 14767/2018). Informed consent was obtained from all the patients before their inclusion in the study. The study was carried out according to the Declaration of Helsinki.

PDF download